Asset profile
TJ202
Monoclonal antibody
Evidence outlook · program status
Discontinued (2022-12-14), as a strategic decision by the sponsor
Market-scoped. TJ202 is felzartamab (MOR202/MOR03087/BIIB148), the anti-CD38 antibody licensed to TJ Biopharma for Greater China. The Phase 1 systemic lupus erythematosus study TJ202001SLE101 was terminated with the sponsor's stated reason 'Company development strategy adjustment', actual completion 2022-12-14. The multiple myeloma programme is NOT stopped: TJ Bio announced NMPA acceptance of the myeloma BLA on 2025-01-10 and the product has since been approved in China, and Biogen consolidated worldwide rights in April 2026 while running Phase 3 renal studies. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
Also in development:Systemic Lupus Erythematosus · Phase 1
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
124 competitors in this universe: 13 direct rivals (same mechanism and indication), 0 same-class, 111 same-indication; 30 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| TJ202: this drug | Phase 3 | Monoclonal antibody | CD38 | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Isatuximab | Approved | Monoclonal antibody | CD38 | ||
| BCD-264 | Phase 3 | Monoclonal antibody | CD38 | ||
| CT-P44 | Phase 3 | Monoclonal antibody | CD38 | ||
| HLX15 | Phase 3 | Monoclonal antibody | CD38 | ||
| Mezagitamab | Phase 3 | Monoclonal antibody | CD38 | ||
| QL2109 | Phase 3 | Monoclonal antibody | CD38 | ||
| SCTC21C | Phase 3 | Biologic (subtype unspecified) | CD38 | ||
| SG301 | Phase 3 | Monoclonal antibody | CD38 | ||
| CID-103 | Phase 1/2 | Monoclonal antibody | CD38 | ||
| CM313 | Phase 1/2 | Monoclonal antibody | CD38 | ||
| STI-6129 | Phase 1/2 | Antibody–drug conjugate | CD38 | ||
| SAR442085 | Phase 1 | Biologic (subtype unspecified) | CD38 | ||
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor, Type I interferon receptor subunit 1 (IFNAR1) | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) |
…and 109 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
7 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.